[go: up one dir, main page]

AU2002213990A1 - Methods for diagnosing and treating huntington's disease - Google Patents

Methods for diagnosing and treating huntington's disease

Info

Publication number
AU2002213990A1
AU2002213990A1 AU2002213990A AU1399002A AU2002213990A1 AU 2002213990 A1 AU2002213990 A1 AU 2002213990A1 AU 2002213990 A AU2002213990 A AU 2002213990A AU 1399002 A AU1399002 A AU 1399002A AU 2002213990 A1 AU2002213990 A1 AU 2002213990A1
Authority
AU
Australia
Prior art keywords
disease
diagnosing
huntington
adenosine
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213990A
Inventor
Mariapia Abbracchio
Pier Andrea Borea
Flaminio Nicola Cattabeni
Elena Cattaneo
Katia Varani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Milano
Universita degli Studi di Ferrara
Original Assignee
Universita degli Studi di Milano
Universita degli Studi di Ferrara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Milano, Universita degli Studi di Ferrara filed Critical Universita degli Studi di Milano
Publication of AU2002213990A1 publication Critical patent/AU2002213990A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)

Abstract

The invention is based on the identification of abnormal behaviour of the adenosine A2A receptor, both as regards the bond to specific ligands and its coupling to the adenylate cyclase system characteristic of cells genetically predisposed to develop Huntington's Disease and of circulating cells in patients affected by this disease. The present invention uses this abnormal behaviour as a diagnostic marker for early detection of the onset and/or progression of this disease, and as a pharmacological target to inhibit to delay progression of the pathology. The invention consists in an in-vitro method for diagnosing Huntington's disease based on assessment of the increase in the number of A2A receptors for adenosine and/or of the abnormal activity of adenylate cyclase, and in the use of drugs that inhibit this activity, for the prevention and/or treatment of this disease.
AU2002213990A 2000-10-03 2001-10-03 Methods for diagnosing and treating huntington's disease Abandoned AU2002213990A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2000MI002137A IT1318960B1 (en) 2000-10-03 2000-10-03 METHOD FOR DIAGNOSIS OF HUNTINGTON KOREA AND ITS TREATMENT METHOD BASED ON THE ACTIVITY OF THE ADENYLATE CYCLASE.
PCT/EP2001/011425 WO2002029408A2 (en) 2000-10-03 2001-10-03 Methods for diagnosing and treating huntington's disease
ITMI2000A002137 2002-10-03

Publications (1)

Publication Number Publication Date
AU2002213990A1 true AU2002213990A1 (en) 2002-04-15

Family

ID=11445897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213990A Abandoned AU2002213990A1 (en) 2000-10-03 2001-10-03 Methods for diagnosing and treating huntington's disease

Country Status (7)

Country Link
US (1) US20040023312A1 (en)
EP (1) EP1325335B1 (en)
AT (1) ATE323287T1 (en)
AU (1) AU2002213990A1 (en)
DE (1) DE60118763D1 (en)
IT (1) IT1318960B1 (en)
WO (1) WO2002029408A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375194B2 (en) 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
US20040049484A1 (en) * 2002-09-11 2004-03-11 Hamano Life Science Research Foundation Method and apparatus for separating and extracting information on physiological functions
WO2010065927A2 (en) 2008-12-05 2010-06-10 California Institute Of Technology Dna-damage-induced proteolysis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9819382D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II

Also Published As

Publication number Publication date
WO2002029408A3 (en) 2002-12-12
WO2002029408A2 (en) 2002-04-11
ATE323287T1 (en) 2006-04-15
ITMI20002137A0 (en) 2000-10-03
US20040023312A1 (en) 2004-02-05
EP1325335A2 (en) 2003-07-09
DE60118763D1 (en) 2006-05-24
IT1318960B1 (en) 2003-09-19
ITMI20002137A1 (en) 2002-04-03
EP1325335B1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
Davis et al. Stress-induced activation of prefrontal cortex dopamine turnover: blockade by lesions of the amygdala
Tidey et al. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study
Németh et al. Adenosine receptor activation ameliorates type 1 diabetes
Van Glabbeke et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)
Lanteri‐Minet et al. Differential time course and spatial expression of Fos, Jun, and Krox‐24 proteins in spinal cord of rats undergoing subacute or chronic somatic inflammation
Kitano et al. Increasing-current electroshock seizure test: a new method for assessment of anti-and pro-convulsant activities of drugs in mice
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
Adlard et al. A comparison of the effects of cytosine arabinoside and adenine arabinoside on some aspects of brain growth and development in the rat
WO2005098429A3 (en) System and method for real-time diagnosis, treatment, and therapeutic drug monitoring
Duman et al. Glucocorticoid administration increases receptor-mediated and forskolin-stimulated cyclic AMP accumulation in rat brain cerebral cortical slices
AU2002213990A1 (en) Methods for diagnosing and treating huntington's disease
Gáspár et al. Different roles of α2-adrenoceptor subtypes in non-pregnant and late-pregnant uterine contractility in vitro in the rat
MXPA05008805A (en) Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases.
GR3021452T3 (en) Method for the detection of gastric epithelial damage.
WO2006017573A3 (en) Method for the early detection of pancreatic cancer and other gastrointestinal disease conditions
Mally et al. Delayed development of symptomatic improvement by (−)-deprenyl in Parkinson's disease
Mulholland et al. Prostaglandin E2 stimulation of acetylcholine release from guinea pig myenteric plexus neurons
MacGregor et al. Does nifedipine reveal a functional abnormality of arteriolar smooth muscle cell in essential hypertension—the effect of altering sodium balance
Marek et al. Genetic influences on brain stimulation-produced analgesia in mice. I. Correlation with stress-induced analgesia
WO2004036221A3 (en) Compositions and methods for diagnosing and treating autoimmune disease
Vogel et al. Activity on the gastrointestinal tract
Hansbrough et al. Prevention of suppressed cell-mediated immunity in burned mice with histamine-2 receptor antagonist drugs
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
GJÖRSTRUP Effects of some α‐adrenoceptor stimulating and blocking agents on the salivary amylase secretion in the rabbit
Bobbin et al. Asphyxia and depolarization increase adenosine levels in perilymph